12:30 PM EST - BriaCell Therapeutics Corp. : Has initiated dosing in a Phase I/IIa clinical study of its lead product candidate, Bria-IMT™, in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced breast cancer whose disease has progressed following standard of care therapies. No effective treatment options for this patient population currently exists making advanced breast cancer an unmet medical need. BriaCell Therapeutics Corp.
shares V.BCT are trading unchanged at $0.06.
